GO:0070670 response to interleukin-4: Genes & Methods

GO:0070670 response to interleukin-4 is a Gene Ontology biological process term that captures the full spectrum of cellular and organismal changes elicited by interleukin-4 (IL-4). According to the QuickGO definition, it encompasses any process that results in a change in state or activity of a cell or an organism, including movement, secretion, enzyme production and gene expression, as a result of an IL-4 stimulus. IL-4 is a pleiotropic cytokine best known for its central role in type 2 immune responses, and its receptor system is among the most intensively studied cytokine networks in immunology. The term is therefore essential for annotating gene products that mediate IL-4 sensing, signal transduction and downstream effector programs. Researchers studying allergy, asthma, atopic dermatitis, chronic rhinosinusitis and cancer immunology routinely encounter GO:0070670 because IL-4 sits at the nexus of type 2 inflammation and immune regulation. The IL-4/IL-13 pathway has become a validated therapeutic target, with biologics directed against IL-4Rα or IL-4 itself showing clinical benefit in type 2 inflammatory diseases. Beyond allergy, ovarian cancer-derived IL-4 has been shown to promote immunotherapy resistance, expanding the disease relevance of this GO term into oncology. Understanding GO:0070670 also requires appreciation of the cellular sources of IL-4. Nasal mucosal fibroblasts can produce IL-4 to induce Th2 responses, and mast cells both produce and respond to IL-4 and IL-13, illustrating autocrine and paracrine loops that amplify type 2 inflammation. Serum IL-4 levels have even been explored as a predictive biomarker for topical immunotherapy in alopecia areata, underscoring the translational reach of this process. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0070670, its core mechanisms, key genes and experimental models.

In plain terms, GO:0070670 response to interleukin-4 is the collection of all changes a cell or organism undergoes after encountering IL-4. The QuickGO definition states: Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus. This biological process term is not restricted to a single pathway; it includes receptor binding, signal transduction, transcriptional reprogramming and functional outputs such as cytokine secretion or cell migration. Its synonym, response to IL-4, is commonly used in the literature.

GO:0070670 is important because IL-4 is a master regulator of type 2 immunity, and its response program shapes outcomes in allergy, autoimmunity and cancer. The IL-4/IL-13 pathway is a validated therapeutic axis in chronic rhinosinusitis with nasal polyps and atopic dermatitis, making annotation of IL-4-responsive genes directly relevant to drug target discovery. In oncology, ovarian cancer-derived IL-4 promotes immunotherapy resistance, so understanding this GO term can inform combination strategies. The breadth of IL-4 sources, from nasal mucosal fibroblasts to mast cells, further underscores why this process is central to mucosal and systemic immunity.

The following genes and proteins are central to the response to interleukin-4, spanning ligand, receptor, signaling and effector functions.

The response to interleukin-4 is regulated at multiple levels. Receptor complex composition determines which cells can respond, because type I and type II IL-4 receptors are differentially expressed and can engage IL-4 and IL-13 with different affinities. Signaling is controlled by JAK-mediated phosphorylation and by negative feedback regulators that dampen STAT6 activity. In disease contexts, the pathway can be amplified by autocrine and paracrine loops, such as IL-4 production by nasal mucosal fibroblasts or mast cells, which sustains type 2 inflammation. Therapeutic regulation of the pathway is achievable with biologics targeting IL-4Rα or the IL-4/IL-13 axis, which has proven effective in type 2 inflammatory diseases.

Chronic rhinosinusitis with nasal polyps is characterized by type 2 inflammation driven in part by the IL-4/IL-13 pathway. The response to interleukin-4 contributes to mucus production, eosinophilic infiltration and polyp formation, and targeting this pathway is a validated therapeutic strategy. This makes GO:0070670 directly relevant to understanding and treating upper airway inflammatory disease.

IL-4, IL-13 and IL-22 play distinct roles in human skin barrier dysfunction and atopic dermatitis. The response to interleukin-4 can alter keratinocyte differentiation and barrier gene expression, contributing to the clinical features of atopic dermatitis. This connection positions GO:0070670 as a key process for dermatological research and therapeutic development.

Ovarian cancer-derived IL-4 promotes immunotherapy resistance, demonstrating that the response to interleukin-4 can shape tumor immune evasion. This finding extends the disease relevance of GO:0070670 beyond allergy into oncology and suggests that IL-4 pathway blockade could improve immunotherapy outcomes.

Serum IL-4 levels have been investigated as predictors of response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. This illustrates how the response to interleukin-4 can serve as a biomarker axis in immune-mediated hair loss.

RNA sequencing before and after IL-4 stimulation is a standard approach to identify genes whose expression changes as part of GO:0070670. This method can reveal STAT6-dependent and independent transcriptional programs and has been applied to contexts such as skin barrier dysfunction and type 2 inflammation.

Western blotting or phospho-flow cytometry can measure JAK and STAT phosphorylation after IL-4 stimulation, providing a direct readout of receptor-proximal signaling. These assays are useful for validating receptor complex usage and for testing the effects of CRISPR-mediated gene knockout.

ELISA or multiplex cytokine assays can quantify secretion of IL-4 and other cytokines, one of the outputs explicitly included in the GO definition. Such assays have been used to study IL-4 production by nasal mucosal fibroblasts and mast cells.

Serum IL-4 measurement has been explored as a predictive biomarker for topical immunotherapy response in alopecia areata, illustrating how the response to interleukin-4 can be monitored in patient samples. Similar approaches can be applied to other type 2 inflammatory diseases.

Researchers studying response to interleukin-4-related genes often need to determine whether a candidate gene is causally involved in IL-4 sensing, signaling or downstream outputs. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations of IL4, IL4R, STAT6 and other pathway components, supporting mechanistic studies of GO:0070670.

GO:0070670 response to interleukin-4 is a foundational biological process term that captures how cells and organisms sense and react to IL-4. Its mechanisms span receptor engagement, JAK/STAT signaling, transcriptional reprogramming and diverse cellular outputs, with well-established roles in type 2 inflammation, skin barrier dysfunction and cancer immunotherapy resistance. Understanding this process is essential for immunology, allergy and oncology research, and for the development of therapeutics targeting the IL-4/IL-13 axis. CRISPR-based cell models provide a powerful approach to dissect the causal contributions of individual genes within this pathway.